Moderna and Merck Report Success in mRNA Cancer Vaccine Melanoma Trial
Pharmaceutical partners Moderna and Merck announced Wednesday that their individually tailored mRNA cancer vaccine demonstrated efficacy in a Phase 3 trial for melanoma patients. The treatment, combined with Merck's Keytruda, significantly reduced the risk of recurrence.
Moderna and Merck announced on Wednesday that their experimental mRNA cancer vaccine, mRNA-4157/V940, has shown positive results in a late-stage clinical trial for patients with melanoma. The vaccine is designed to target specific mutations within a patient's tumor.
The Phase 3 trial involved 1,137 patients with surgically removed stage IIB-IV melanoma. Participants were randomly assigned to receive either the combination of the mRNA vaccine and Merck's immunotherapy drug Keytruda, or Keytruda alone. The trial was placebo-controlled and double-blind.
While detailed data has not yet been released, the companies stated that the combination therapy significantly reduced the risk of cancer recurrence or death compared to Keytruda alone. This marks a potential significant advancement for personalized cancer vaccines.
If these findings are confirmed with further data analysis, it could represent a major breakthrough for mRNA technology in oncology and usher in a new era of personalized cancer treatments.